GoAI
Get started
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc.

PBYI

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$9.24

+$0.13 · +1.43%

Aug 21, 4:00 PM ET

PBYI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

88

Deep Value

Momentum

71

Gaining

Sentiment

72

Bullish

Risk resilience

61

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Alan H. Auerbach
Listed since
Apr 24, 2012
Employees
179

Market position

Day range

Current $9.24

52-week range

Current $9.24

Open
$9.21
Previous close
$9.11
Volume
333.62K
1.1× average
Average volume
303.88K
Average daily volume
Market cap
470.31M USD
Beta
1.22
Market reference 1
50-day average
$8.1624
+13.20% above average
200-day average
$6.8511
+34.87% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
17.23×
P/B (TTM)
3.4×
P/S (TTM)
2.03×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
74.83%
Operating margin
13.16%
Net margin
11.55%

Financial health

Debt / equity
0.03×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends85%50%15%-20%Gross margin, FY2021: 74.84%Gross margin, FY2022: 75.84%Gross margin, FY2023: 73.40%Gross margin, FY2024: 72.06%Gross margin, FY2025: 74.53%Operating margin, FY2021: 0.51%Operating margin, FY2022: 10.40%Operating margin, FY2023: 13.85%Operating margin, FY2024: 13.44%Operating margin, FY2025: 16.33%Net margin, FY2021: -11.51%Net margin, FY2022: 0.00%Net margin, FY2023: 9.16%Net margin, FY2024: 13.14%Net margin, FY2025: 13.62%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 74.84%. Gross margin FY2022 75.84%. Gross margin FY2023 73.40%. Gross margin FY2024 72.06%. Gross margin FY2025 74.53%. Operating margin FY2021 0.51%. Operating margin FY2022 10.40%. Operating margin FY2023 13.85%. Operating margin FY2024 13.44%. Operating margin FY2025 16.33%. Net margin FY2021 -11.51%. Net margin FY2022 0.00%. Net margin FY2023 9.16%. Net margin FY2024 13.14%. Net margin FY2025 13.62%.

Income trends

Revenue

228.37M USD-0.91%

Operating income

37.3M USD+20.45%

Net income

31.11M USD+2.75%
Income trends across reported periods281.38M USD168.47M USD55.56M USD−57.35M USDRevenue, FY2021: 253.16M USDRevenue, FY2022: 228.03M USDRevenue, FY2023: 235.64M USDRevenue, FY2024: 230.47M USDRevenue, FY2025: 228.37M USDOperating income, FY2021: 1.29M USDOperating income, FY2022: 23.72M USDOperating income, FY2023: 32.64M USDOperating income, FY2024: 30.97M USDOperating income, FY2025: 37.3M USDNet income, FY2021: −29.13M USDNet income, FY2022: 2K USDNet income, FY2023: 21.59M USDNet income, FY2024: 30.28M USDNet income, FY2025: 31.11M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 253.16M USD. Revenue FY2022 228.03M USD. Revenue FY2023 235.64M USD. Revenue FY2024 230.47M USD. Revenue FY2025 228.37M USD. Operating income FY2021 1.29M USD. Operating income FY2022 23.72M USD. Operating income FY2023 32.64M USD. Operating income FY2024 30.97M USD. Operating income FY2025 37.3M USD. Net income FY2021 −29.13M USD. Net income FY2022 2K USD. Net income FY2023 21.59M USD. Net income FY2024 30.28M USD. Net income FY2025 31.11M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue228.37M USD230.47M USD235.64M USD228.03M USD253.16M USD
Cost of goods sold58.16M USD64.4M USD62.68M USD55.09M USD63.7M USD
Gross profit170.21M USD166.06M USD172.96M USD172.94M USD189.45M USD
Research and development62.07M USD54.94M USD50.38M USD52.24M USD71.87M USD
Selling, general, and administrative71.21M USD80.16M USD89.31M USD89.98M USD116.29M USD
Operating expenses132.92M USD135.1M USD140.32M USD149.22M USD188.16M USD
Interest income4.08M USD4.72M USD2.61M USD813K USD160K USD
Interest expense6.62M USD12.45M USD13.33M USD11.59M USD12.81M USD
Depreciation and amortization10.94M USD11.52M USD11.52M USD9.84M USD11.31M USD
Operating income37.3M USD30.97M USD32.64M USD23.72M USD1.29M USD
Net income31.11M USD30.28M USD21.59M USD2K USD−29.13M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

20 ratings
Strong buy00%
Buy840%
Hold840%
Sell420%
Strong sell00%

PBYI news

zacks.com

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and…

Read source
zacks.com

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.

Read source
seekingalpha.com

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Puma Biotechnology Q2 Earnings Call Highlights

Puma Biotechnology NASDAQ: PBYI reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The company posted GAAP net…

Read source
zacks.com

Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates

Puma Biotech (PBYI) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.15 per share a year ago.

Read source
businesswire.com

Puma Biotechnology Reports Second Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call beginning at 1:30 p.m. PT on Aug. 6, following release of its earnings results for 2Q-2026.

Read source

PBYI peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding PBYI

Funds reporting this stock among their holdings, ordered by reported position size.

Avantis U.S. Small Cap Value ETF logoAvantis U.S. Small Cap Value ETFAVUV
Market value
20.33M
Weight
0.07%
AUM
31.27B USD
Expense ratio
0.25%
Price / 1D
$126.45+0.66%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
10.65M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
10.56M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
3.54M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
3.26M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Invesco Dorsey Wright SmallCap Momentum ETF logoInvesco Dorsey Wright SmallCap Momentum ETFDWAS
Market value
2.16M
Weight
0.49%
AUM
434.69M USD
Expense ratio
0.60%
Price / 1D
$114.27+1.10%
EA Bridgeway Omni Small-Cap Value ETF logoEA Bridgeway Omni Small-Cap Value ETFBSVO
Market value
2.14M
Weight
0.09%
AUM
1.71B USD
Expense ratio
0.47%
Price / 1D
$29.62+0.85%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.97M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%

Continue in GoAI

Research PBYI

research.disclaimer